---
schema_version: "secwatch.filing_event.v1"
accession: "0000875045-23-000005"
form_type: "8-K"
ticker: "BIIB"
cik: "0000875045"
company_name: "BIOGEN INC."
filed_at: "2023-02-15T23:59:59+00:00"
generated_at: "2026-06-19T12:40:47.204160+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Biogen Q4 2022 rev $2.54B; GAAP EPS $3.79; guides FY2023 Non-GAAP EPS $15-$16

## Summary
- Q4 revenue $2,544M, GAAP EPS $3.79, Non-GAAP EPS $4.05.
- FY2022 revenue $10,173M (-7% YoY); GAAP EPS $20.87; Non-GAAP EPS $17.67 (-8% YoY).
- FY2023 guidance: mid-single digit revenue decline; Non-GAAP EPS $15.00-$16.00.
- LEQEMBI (lecanemab) granted FDA accelerated approval; traditional filing submitted in US, EU, Japan, China.
- Zuranolone NDA for MDD/PPD accepted with Priority Review; PDUFA date August 5, 2023.

## SEC filing metadata
- accession: 0000875045-23-000005
- form_type: 8-K
- ticker: BIIB
- cik: 0000875045
- company_name: BIOGEN INC.
- filed_at: 2023-02-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875045/000087504523000005/0000875045-23-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875045/000087504523000005/biib-20230215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875045-23-000005
- JSON: https://secwatch.observer/filing/0000875045-23-000005.json
- Plain text: https://secwatch.observer/filing/0000875045-23-000005.txt

## Key facts
- Earnings Releases
  BIOGEN INC. reported the fourth quarter and year ended December 31, 2022 results: revenue $2,544 million, net income GAAP diluted EPS $3.79; Non-GAAP diluted EPS $4.05, EPS GAAP diluted EPS $3.79; Non-GAAP diluted EPS $4.05.
  - Period: the fourth quarter and year ended December 31, 2022
  - Revenue: $2,544 million
  - Net income: GAAP diluted EPS $3.79; Non-GAAP diluted EPS $4.05
  - EPS: GAAP diluted EPS $3.79; Non-GAAP diluted EPS $4.05
  - Result: reported results
  source text: growth drivers; Company reports full year 2022 results and provides full year 2023 guidance Full year 2022 revenue and Non-GAAP EPS exceed guidance • Fourth quarter revenue $2,544 million; GAAP diluted EPS $3.79; Non-GAAP diluted EPS $4.05 • Full year revenue $10,173 million; GAAP diluted EPS $20.87; Non-GAAP diluted EPS $17.67 Positioned to lead in Alzheimer’s
  evidence_url: https://www.sec.gov/Archives/edgar/data/875045/000087504523000005/0000875045-23-000005-index.htm
- Earnings Releases
  BIOGEN INC. reported full year 2023 results: EPS $15.00 to $16.00. Guidance initiated.
  - Period: full year 2023
  - EPS: $15.00 to $16.00
  - Guidance: initiated
  - Result: guidance update
  source text: Full Year 2023 Financial Guidance • Expect mid-single digit revenue decline versus 2022 and Non-GAAP EPS of $15.00 to $16.00
  evidence_url: https://www.sec.gov/Archives/edgar/data/875045/000087504523000005/0000875045-23-000005-index.htm
- Earnings Releases
  BIOGEN INC. reported full year 2022 results: revenue $10,173 million, net income GAAP diluted EPS $20.87; Non-GAAP diluted EPS $17.67, EPS GAAP diluted EPS $20.87; Non-GAAP diluted EPS $17.67.
  - Period: full year 2022
  - Revenue: $10,173 million
  - Net income: GAAP diluted EPS $20.87; Non-GAAP diluted EPS $17.67
  - EPS: GAAP diluted EPS $20.87; Non-GAAP diluted EPS $17.67
  - Result: reported results
  source text: Full year revenue $10,173 million; GAAP diluted EPS $20.87; Non-GAAP diluted EPS $17.67
  evidence_url: https://www.sec.gov/Archives/edgar/data/875045/000087504523000005/0000875045-23-000005-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.